IL6 and neoplasm: Both selected SOMAmers prevent IL-6 signaling by blocking the interaction of IL-6 with its receptor (schematically represented in Figure 2(i)) and inhibit the in vitro proliferation of tumor cells at levels of efficacy comparable to those of the anti-IL-6 mAb tocilizumab [38].